Research
Loading latest report…
Loading research access…
Information on this site is for informational purposes only and is not investment advice. Always do your own research and consult a licensed advisor before making financial decisions. Data timestamps use US Eastern Time unless noted.
J.P. Morgan
Oct 30, 2026 · ILMN
Tags: ILMN earnings-review clinical-sequencing NovaSeq-X AI-data
Value Score: 8/10
Core Conclusion: JPMorgan retains Overweight but cuts Illumina's December 2027 target from $320 to $300. Strong US clinical sequencing and continued NovaSeq X placements support consumables growth, while elevated expectations require clearer evidence of durable demand, improving research markets and incremental data revenue.
Third-quarter revenue was approximately $1.13bn as reported, including a $37m reduction associated with expected tariff-refund credits to customers. Excluding that impact, the comparable figure was $1.17bn versus $1.15bn consensus, with 4.8% organic growth. The report's subsequent operating comparisons exclude the refund impact.
Adjusted EPS of $1.44 exceeded $1.36 consensus. Adjusted gross margin reached 69.4% and operating margin 25.0%, above consensus of 68.8% and 24.0%. These results support the margin recovery, but do not change the uneven composition of demand.
US clinical sequencing consumables grew more than 20%. Clinical consumables outside China grew 14%, down from 15% in the prior quarter, while research and applied consumables declined 6%. Europe was weak for a second quarter, offsetting stronger US clinical activity.
More than 80 NovaSeq X instruments were placed, versus JPMorgan's expectation of 70. Sequencing instrument revenue nevertheless declined 1% organically, reflecting weakness elsewhere in the portfolio. Installed capacity is therefore a leading indicator for recurring consumables rather than evidence of broad instrument-market recovery.
NovaSeq X accounts for approximately 84% of high-throughput sequencing volume but around 60% of high-throughput consumables revenue. As the migration matures, management expects less transition-related pricing drag in 2027. Volume expansion must still outweigh lower revenue per unit of sequencing and competitive pricing.
Management raises 2026 revenue guidance, excluding the refund impact, to $4.64-4.66bn and adjusted EPS to $5.40-5.45. The outlook for organic growth outside China remains above 5%. Fourth-quarter EPS guidance of $1.51-1.56 brackets $1.54 consensus, with approximately 25% adjusted opera
